The Institute@Precision Asia-Pacific Series
Commercialization & Access
China Market Access After NRDL Maturity: What Comes After the Price Reset?
Commercialization & Access | White Paper
China Market Access After NRDL Maturity: What Comes After the Price Reset?
NRDL inclusion is no longer the finish line. See why reimbursement alone doesn’t guarantee real-world utilization.
Research & Development | White Paper
The APAC Imperative for Phase III Trials
The benefits of running your Phase III trial in APAC are established. Learn why so many organizations struggle to realize them.
Commercialization & Access | White Paper
The Role of Societal Value Analyses in Supporting Access to Novel Pharmacotherapies in Asia-Pacific Markets
See how looking beyond clinical value can strengthen your case with payers and policymakers.
Get closer
From scientific breakthroughs to shifts in policy and practice, bring the next big advances in biopharma into sharper focus.
Research & Development | White Paper
The APAC Imperative for Phase III Trials
Commercialization & Access | White Paper
The Role of Societal Value Analyses in Supporting Access to Novel Pharmacotherapies in Asia-Pacific Markets
Commercialization & Access | White Paper
China Market Access After NRDL Maturity: What Comes After the Price Reset?
Research & Development | White Paper
Managing Operational Complexity in Early-Phase Oncology Radiopharmaceutical Trials
Commercialization & Access | White Paper
Challenges and Opportunities for Radiopharmaceutical Commercialization
Research & Development | White Paper
Navigating Global Regulations for Radiopharmaceutical Development
Commercialization & Access | White Paper
Wall Street Perspective on Radiopharmaceuticals
Research & Development | White Paper
Advancing Radiopharmaceuticals From Regulatory Approval to Global Access
Research & Development | White Paper
Moving ADCs to the front-line: Perspectives from FDA Oncology Experts
Research & Development | White Paper
The ADC Pendulum: Understanding ADC Withdrawals to build better therapies
Commercialization & Access | Industry Brief
HEOR Value demonstration for Antibody-Drug Conjugates: Lessons learned from the first 25 years.
Commercialization & Access | Industry Brief
Twenty-Five Years of Antibody–Drug Conjugates: From Breakthroughs to Access by Design
.jpg?length=720&name=Market%20Outlook%20Q4%202025_%20Antibody-Drug%20Conjugates%20(ADCs).jpg)
Commercialization & Access | White Paper
Market Outlook Q4 2025: Antibody-Drug Conjugates (ADCs)
Research & Development | White Paper
Cohort Management: Best Practices for Early Phase Oncology Clinical Trials
Research & Development | White Paper
Designing Seamless Phase 1/2 Oncology Trials
Research & Development | Poster
Validation of an approach to measure high levels of neutralizing antibodies against AAV in human serum samples
Research & Development | Poster
PD-L1 Expression on Immune Cells from Solid Tumor Patients: Implications for Tumor Immunity and Immunotherapy
Research & Development | Poster
Utilization of Multiparameter Flow Cytometry for Immune Monitoring of Tumor Infiltrating Lymphocytes Isolated from Fresh Tumor Tissue
Research & Development | Industry Brief
Immune Cell Profiling in Translational Research
Research & Development | Industry Brief
Characterized Biospecimens: A Guide for Leveraging Deeply Characterized Biospecimens to Support Successful Therapeutic & Diagnostic Development
Research & Development | Industry Brief
Journey of a Therapeutic Antibody: From Preclinical to Clinical Proof of Concept Development
Research & Development | White Paper
Guide to Successfully Conducting Tissue Cross-Reactivity Studies
Research & Development | White Paper
Optimizing Successful Gene Therapy Development
Research & Development | White Paper
Quantitative Multiplex Immunofluorescence : A Powerful Tool for Oncology Therapeutic Development
Research & Development | White Paper
Breaking Through in Hematologic Malignancies
Research & Development | White Paper
Exploring the Intricacies of the Immune System: A Practical Guide to Immune Monitoring Across Therapeutic Interventions
Research & Development | Industry Brief
Phase 3 Prostate Cancer Case Study: Radiopharm Imaging at Scale
Research & Development | Article
Why Antibody-Drug Conjugates Are Revolutionizing Precision Oncology
Research & Development | Article
Clinical Trial Trends: Antibody-Drug Conjugates
Research & Development | Industry Brief
Understanding Immunogenicity and AAV Gene Therapy
Research & Development | Poster
Validation of an IFN-y ELISpot Assay for Measuring T-Cell Responses Against Viral Antigens, in AAV-based Gene Therapy
Commercialization & Access | Article
Leveraging Early Access/Compassionate Use Pathways to Provide Market-Specific Real-World Evidence Before Launch
Commercialization & Access | White Paper
How Health Systems Are Using AI In Clinical Decision-Making
Commercialization & Access | White Paper
How to align Pricing & Contracting with Stakeholder Needs
Commercialization & Access | White Paper
Shifting Oncology Management Strategies Among Payers and Providers
Commercialization & Access | Industry Brief
Securing Access & Reimbursement for Rare Disease Therapies
Commercialization & Access | White Paper
Why Cardiovascular-Kidney-Metabolic Health Is a Priority for Payers & What It Means for Manufacturers
Commercialization & Access | Industry Brief
Caregiving in Alzheimer’s and Related Dementias: Finding Opportunities to Optimize Caregiver Support
Commercialization & Access | Industry Brief
Innovation and Challenges in Cell & Gene Therapy
Commercialization & Access | White Paper
Navigating 340B and Rebates: Challenges, Solutions, and the Path Forward
Commercialization & Access | White Paper
Innovation, Personalization & the Future of Oncology: How AI Is Transforming Cancer Care
Commercialization & Access | Industry Brief
Architecting the Future Of Prior Authorization: A Blueprint for Scalable Automation Under The CMS Interoperability Mandate
Research & Development | White Paper
Evolutions In Oncology Cell Therapy
Commercialization & Access | Article
Exploring Decision-makers' Challenges and Strategies When Selecting Multiple Systematic Reviews
Commercialization & Access | Article
The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic Diseases
.jpg?length=720&name=Methods%20for%20Incorporating%20Non-Randomized%20Evidence%20From%20Single-Arm%20Trials%20Into%20Network%20Meta-Analysis%20(NMA).jpg)
Commercialization & Access | Article
Methods for Incorporating Non-Randomized Evidence From Single-Arm Trials Into Network Meta-Analysis (NMA)
Commercialization & Access | Presentation
Can Distributional Cost Effectiveness Analysis Actually Inform On and Improve Health Equity in Oncology?
Commercialization & Access | Article
Pembrolizumab Plus Chemotherapy For First-line Treatment Of Advanced Triple-negative Breast Cancer
Commercialization & Access | Article
Clinical Outcomes of PD-1/PD-L1 Inhibitors Among Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Commercialization & Access | Article
Pros and Cons of Various Reimbursement Models for Cell and Gene Therapies
Commercialization & Access | Article
Improving Patient Access to Cell Therapy Through Decentralized Manufacturing
Commercialization & Access | Article
Payer Challenges for Patient Access to Autologous Cell and Gene Therapies
Commercialization & Access | Article
Payors, Pharma Engage Alternative Payment Models Amid High Gene Therapy Cost, Efficacy Unknowns
Commercialization & Access | Article
AI-Powered Real-World Evidence Generation For Biotechs
Commercialization & Access | Article
FDA Accelerated Approval: Implications For Treatment Innovation In Oncology
Research & Development | Article
CGT Is In Its Infancy For CNS Disorders, But Technical Strides Being Made
Research & Development | Article
Are Rare Brain Diseases the Next Commercial Frontier for Gene Therapy?